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Background: Sex and gender-related factors have been under-investigated as relevant
determinants of health outcomes across non-communicable chronic diseases. Poor
medication adherence results in adverse clinical outcomes and sex differences have been
reported among patients at high cardiovascular risk, such as diabetics. The effect of
diabetes and gender-related factors on medication adherence among women and men
at high risk for ischemic heart disease (IHD) has not yet been fully investigated.
Aim: To explore the role of sex, gender-related factors, and diabetes in pre-admission
medication adherence among patients hospitalized for IHD.
Materials and Methods: Data were obtained from the Endocrine Vascular disease
Approach (EVA) (ClinicalTrials.gov Identifier: NCT02737982), a prospective cohort of
patients admitted for IHD. We selected patients with baseline information regarding
the presence of diabetes, cardiovascular risk factors, and gender-related variables (i.e.,
gender identity, gender role, gender relations, institutionalized gender). Our primary
outcome was the proportion of pre-admission medication adherence defined through
a self-reported questionnaire. We performed a sex-stratified analysis of clinical and
gender-related factors associated with pre-admission medication adherence.
Results: Two-hundred eighty patients admitted for IHD (35% women, mean
age 70), were included. Around one-fourth of the patients were low-adherent
to therapy before hospitalization, regardless of sex. Low-adherent patients were
more likely diabetic (40%) and employed (40%). Sex-stratified analysis showed
that low-adherent men were more likely to be employed (58 vs. 33%) and
not primary earners (73 vs. 54%), with more masculine traits of personality, as
compared with medium-high adherent men. Interestingly, women reporting medication
low-adherence were similar for clinical and gender-related factors to those with medium-
high adherence, except for diabetes (42 vs. 20%, p = 0.004). In a multivariate
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adjusted model only employed status was associated with poor medication adherence
(OR 0.55, 95%CI 0.31–0.97). However, in the sex-stratified analysis, diabetes was
independently associated with medication adherence only in women (OR 0.36; 95%CI
0.13–0.96), whereas a higher masculine BSRI was the only factor associated with
medication adherence in men (OR 0.59, 95%CI 0.35–0.99).
Conclusion: Pre-admission medication adherence is common in patients
hospitalized for IHD, regardless of sex. However, patient-related factors such as
diabetes, employment, and personality traits are associated with adherence in a
sex-specific manner.
Keywords: sex, gender, diabetes, medication adherence, ischemic heart disease, personality traits, employment
status
INTRODUCTION
Poor medication adherence to long-term pharmacological
therapies is a public health concern that affects mostly patients
with non-communicable chronic diseases (1, 2) such as type 2
diabetes mellitus and ischemic heart disease (IHD), both global
epidemics of the twenty-first century for men and women (3–5).
Among diabetic patients, the non-adherence to glucose-lowering
drugs results in a suboptimal glycemic control with higher risk
of diabetes-related microvascular complications (6, 7). Moreover,
diabetic patients should be treated with cardiovascular drugs
to prevent macrovascular complications including IHD (8–10).
Sex differences in the cardiovascular consequences of diabetes
exist and should be specifically addressed in the management of
diabetic patients (11–13).
Multiple variables affecting physicians and patients contribute
to medication non-adherence, which in turn negatively affects
treatment outcomes and causes psychosocial complications,
reduces patients’ quality of life, and wastes health care
resources (14–16). The World Health Organization suggests that
improving adherence requires a multidimensional approach (i.e.,
social and economic factors, health-care team and system-related
factors, condition-related factors, therapy-related factors, and
patient-related factors), highlighting that psycho-socio-cultural
factors need to be considered as contributors (17).
Even though sex- (i.e., biological factors) and gender- (i.e.,
psycho-socio-cultural factors) differences play a very important
role in influencing clinical outcomes, both aspects are generally
overlooked and under-reported (18, 19). While biological sex
variables refer to objectively measurable organs, hormones,
genes, anatomy, and physiology, gender represents a social
construct that is linked to economic and social status (20).
It has several dimensions, including gender identity (how
individuals perceive and present themselves), gender norms
(behavioral expectations based on individual sex including
role in the family, in the workplace, in society, etc.), and
gender relations (emotional and economic relations between
individuals) (21). As sex and gender are not independent,
exclusively assessing one or the other fails to account for
identified variations in health (22, 23). Specifically, their role
and interaction as determinants of medication adherence are
still not fully understood. Moreover, the complexity of gender
and the lack of a validated standardized measurement, with
the exception of the GENESIS-PRAXY gender score (23, 24),
both contribute to the paucity of data available including
medication adherence.
Based on a prospective cohort of patients hospitalized for
IHD events, with the unique systematic collection of gender-
related variables, we explored the factors associated with pre-
admissionmedication adherence and whether any sex differences
exist in the effect of diabetes and gender-related variables on
pre-admission medication adherence.
MATERIALS AND METHODS
Data for the present analysis come from the “Endocrine
Vascular disease Approach” (EVA) project (ClinicalTrials.gov
Identifier: NCT02737982), an ongoing prospective observational
study aiming to explore sex and gender differences in the
interaction of platelet function, sex hormone balance, and
coronary microvascular dysfunction in IHD (25). In brief,
EVA is a registry of men and women, aged 18 and older,
who were referred to the cardiac catheterization laboratory
to undergo coronary angiography and/or percutaneous
coronary intervention for suspected IHD, Patients with
active cancer (i.e., currently treated with chemotherapy or
at ≤5 years from diagnosis), current pregnancy, previous
coronary artery bypass graft, documented moderate-severe
valvular heart disease, and prosthetic valve carriers were
excluded. Therefore, the EVA study population includes
patients with stable coronary artery disease, patients with
non-ST elevation acute coronary syndrome and patients with
ST elevation myocardial infarction. The recruitment phase is
still ongoing.
The study was conducted in full conformance with the
principles of the Declaration of Helsinki, the laws and regulations
of Italy, or whichever afforded greater protection to the
individual. The study obtained the required authorization by
the local Ethics Committee of Policlinico Umberto I, Sapienza
University of Rome (reference 3786, 24/09/2015). Written
informed consent has been obtained from all patients.
Among the study population, we selected baseline data from
patients recruited until August 2018.
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Baseline Clinical Characteristics and
Gender-Related Factors
We selected patients with complete information at baseline
regarding: (1) anthropometric data (including height, weight,
blood pressure, heart rate); (2) independent functional status
assessed by the Duke Activity Status Index (26); (3) presence of
diabetes; (4) cardiovascular risk factors including family history
of cardiovascular disease; hypertension; dyslipidemia; chronic
kidney disease; previous cardiovascular events including prior
MI and stent implantation. Patients’ baseline characteristics
were selected from a combination of medical record abstraction
and standardized in-person interviews administrated by
trained personnel.
According to the definition of gender components designed
by the Women’s Health Research Network (21), we collected
the following gender-related factors: (1) gender role: household’s
primary earner status and employment status; (2) gender
relations: marital status (i.e., married/living with partner vs.
others); (3) gender identity: Bem Sex Role Inventory (BSRI)
masculine and feminine (27), and level of stress (defined through
the 10-item perceived stress scale) (28); (4) institutionalized
gender: low socioeconomic status [defined as low education level
(i.e., less than secondary school) and/or low household income
(i.e., <1,000 Euro per month)]. Furthermore, we considered the
following as risk-taking behaviors: alcohol consumption (i.e.,
more than 2 units per day for women and 3 units per day for
men), physical inactivity (defined as no recreational activity or
less than once per week), and smoking habits (current smoker).
All the gender-related variables were collected through self-
reported questionnaires.
Pre-admission Medication Adherence
Assessment
Pre-admission medication adherence has been assessed using
a self-administrated questionnaire at the baseline visit. A
simple self-reported measure of medication adherence, which
has been shown to be predictive of blood pressure control
(29), was used to measure medication-taking behavior (i.e.,
trouble in remembering to take medication, spontaneous
interruption due to personal judgment) among our hospitalized
patients undergoing coronary angiography for suspected
IHD. Polypharmacy was defined as more than 5 drugs
assumed daily by the patient as previously reported (30).
Information concerning the class of drugs taken by the
patient include: antithrombotic agents (i.e., anticoagulants
and antiplatelet drugs), b-adrenergic receptor blockers (b-
blockers), hydroxylmethylglutaryl-coenzyme A reductase
inhibitors (statins), angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers, oral glucose lowering drugs, or
subcutaneous insulin.
Statistical Analysis
After verification of non-normality, continuous variables were
reported as median and interquartile range (IQR). Differences
between the groups (low-adherent vs. medium-high adherent)
were established, according to non-normal distribution, with
a non-parametric test, the Mann-Whitney U-test. Categorical
variables were reported as counts and percentages, and
differences between groups (low-adherent vs. medium-high
adherent) were evaluated with chi-square test or Fisher’s Exact
test when appropriate (cell count<5).
A logistic regression model was computed to identify the
predictors of medium-high adherence. Both in the overall
model, as well as in the sex-stratified analysis, variables which
significantly differed at baseline with a p-value < 0.10 were
identified to be included in a univariate analysis. All variables
associated with adherence for <10% (p < 0.10) at univariate
analysis, were included in the final multivariate model. A two-
sided p-value < 0.05 was considered as statistically significant.
All analyses were performed using SPSS v. 25.0 (IBM, NY, USA).
RESULTS
Among the EVA cohort, 280 (median [IQR] age 70 [63–76]
years; 35% women) patients hospitalized for IHD were analyzed.
Preadmission low-adherence was reported in 24% (n = 67) of
patients, regardless of sex.
Clinical characteristics according to adherence are reported
in Table 1. Low-adherent patients were more likely to be
diabetic as compared with adherent patients. No statistically
significant difference in pre-admission medication adherence
was found between women and men with or without prior
history of IHD (74 vs. 77%, respectively). No differences in age,
sex, blood pressure, body mass index, main cardiovascular co-
morbidities, type of drugs, and polypharmacy were observed
between medium-high adherent and low-adherent subjects. The
distribution of gender-related factors according to pre-admission
medication adherence status is shown in Table 2. The only
gender-related factor statistically more prevalent in low-adherent
patients was to be employed. Other psycho-socio-cultural factors
were similar among the 2 groups.
When data were stratified by sex, we observed that low-
adherentmenweremost likely employed yet not primary earners,
and with more masculine personality traits (Table 3). On the
other hand, low-adherent women were most likely diabetic and
physically inactive, with no statistical differences in any gender-
related factor (Table 4). No differences in the types of drugs taken
were observed in both sexes.
Therefore, we explored the determinants of pre-admission
adherence: only being employed was independently associated
with medication adherence status [Odds Ratio (OR) 0.55, 95%
Confidence Interval (CI) 0.31–0.97, p = 0.041] in our cohort
(Table 5). However, when we stratified the analysis by sex, only
a BSRI masculine (OR 0.59, 95%CI 0.35–0.99, p = 0.048) was
inversely associated with adherence in men, while only diabetes
(OR 0.36; 95%CI 0.13–0.96, p= 0.041) in women (Table 5).
DISCUSSION
Themain findings of our analysis are that: (i) pre-admission poor
adherence was highly prevalent, characterizing more than one
fourth of men and women hospitalized for IHD; (ii) diabetes
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TABLE 1 | Baseline clinical characteristics of EVA patients according to
pre-admission medication adherence.
Low
adherence
(n = 67)
Medium-high
adherence
(n = 213)
p
Age, years median
[IQR]
68 [61–78] 71 [63–76] 0.447
Women, n (%) 24 (35.8) 74 (34.7) 0.872
BMI, kg/m2
median [IQR]
27.0
[24.8–30.0]
26.5 [24.2–29.5] 0.447
SBP, mmHg
median [IQR]
130 [120–150] 130 [120–140] 0.104
DBP, mmHg
median [IQR]
80 [70–85] 80 [70–80] 0.537
HR, bpm median
[IQR]
70 [62–80] 70 [60–76] 0.239
Hypertension 57 (86.4) 181 (85.0) 0.781
Dyslipidemia 41 (61.2) 122 (57.3) 0.571
Type 2 diabetes 27 (40.3) 58 (27.2) 0.042
Active Smoke 15 (22.7) 49 (23.2) 0.934
Alcohol Abuse 11 (16.4) 36 (17.7) 0.805
Physical inactivity 57 (85.1) 167 (78.4) 0.234
History of CAD 28 (41.8) 79 (37.1) 0.490
Vascular disease 21 (31.8) 58 (27.2) 0.470
Stroke/TIA 7 (10.6) 24 (11.3) 0.881
CKD 17 (26.2) 53 (25.7) 0.945
Polypharmacy 38 (56.7) 106 (49.8) 0.321
DASI, median
[IQR]
27.0
[19.0–42.7]
32.2 [19.0–49.8] 0.153
Therapy pre-admission
- Glucose
lowering drugs
17 (25.4) 41 (19.2) 0.281
- Insulin 7 (10.4) 12 (5.6) 0.172
- Statins 32 (47.8) 110 (51.6) 0.579
- Antiplatelets 43 (64.2) 135 (63.4) 0.906
- Anticoagulants 8 (11.9) 19 (8.9) 0.465
- Beta-Blockers 30 (44.8) 96 (45.1) 0.966
- ACEi 19 (28.4) 57 (26.8) 0.798
- ARBs 18 (26.9) 76 (35.7) 0.183
Data are presented as number of patients (%) unless otherwise specified.
IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HR, heart rate; CAD, coronary artery disease; TIA, Transient
ischemic attack; CKD, chronic kidney disease; DASI, Duke Activity Status Index; ACEi,
Angiotensin converting enzyme inhibitors; ARBs, Angiotensin II receptor blockers. When
missing data are more than 10%, they are reported in brackets.
was the only cardiovascular risk factor significantly prevalent
in low-adherent patients with IHD before hospitalization; (iii)
among the gender-related variables, employed status, as proxy
of the gender role, was negatively associated with medication
adherence; and (iv) factors related to pre-admission adherence
differed between sexes, with diabetes being more relevant for
women, while masculine traits of personality were independently
associated with low-adherence in men.
Medication low-adherence is a major and costly obstacle
in the management of common non-communicable chronic
diseases, such as hypertension and diabetes (16, 31, 32). The
TABLE 2 | Gender-related factors of EVA patients according to pre-admission
medication adherence.
Low
adherence
(n = 67)
Medium-High
Adherence
(n = 213)
p
Employed status 27 (40.3) 57 (27.0) 0.039
Primary earner# 19 (38.0) 83 (49.4) 0.156
Male BSRI, median [IQR] 5.0 [4.1–5.6] 4.7 [4.1–5.4] 0.552
Female BSRI, median [IQR] 5.8 [5.2–6.4] 5.9 [5.3–6.2] 0.991
High Stress at home# 14 (29.2) 44 (26.2) 0.682
Married/living with partner 46 (68.7) 149 (70.0) 0.840
Low SES* 36 (53.7) 96 (45.1) 0.215
Data are presented as number of patients (%) unless otherwise specified.
SES, socioeconomic status; BSRI, Bem Sex Role Inventory; *SES was defined based on
low education level and/or personal income. #data available for 215 patients.
prevalence of medication non-adherence varies tremendously
depending on the population studied, the method used for
assessment of medication use (e.g., self-report or pharmacy
refill data) and the specific medications assessed (15, 33–35).
Moreover, significant sex differences were previously reported
in general drug-users in terms of intensity of medication use
and compliance to treatment (36). Interestingly, in our cohort
of patients admitted for an IHD event, the pre-admission poor
medication adherence was similarly high (25%) among women
and men. However, we identified different factors associated
to inappropriate drug behavior among sexes that should be
considered when targeting obstacles for improving patient
adherence to pharmacological treatment.
Diabetes is the only condition that reverses the female
advantage in cardiovascular risk (37). Diabetic women
experience worse clinical outcomes compared to age-matched
diabetic men, especially in the setting of ischemic heart disease
(38). In our cohort, diabetic women hospitalized for an ischemic
coronary event were more likely low-adherent to therapy
before admission. Diabetes was found as the only clinical
determinant of pre-admission medication adherence in a
sex-specific manner, despite the low sample of women enrolled
in the present analysis. On the other hand, diabetes loses its
explanatory power when gender-related factors are considered
in the subgroup of male patients. We provide an example of
how controlling and adjusting the analysis for sex can lead to
a misinterpretation of data, especially when the women are
underrepresented in a study population. Therefore, an analysis
disaggregated by sex might inform our better understanding
of the outcomes of interest in men and women. In fact, the
approach of reporting data disaggregated by sex and a sex-
stratified analysis are recommended by the international clinical
research stakeholders (39, 40).
The distinction between sex and gender, which is clear and
common in the social sciences, has largely been neglected in
health science. In truth, sex and gender are often erroneously
used and/or measured interchangeably (18). The integration
of sex- and gender-based analysis is a much-needed and, yet,
uncommon approach to improving the quality of evidence and
guaranteeing the generalizability of findings. However, when
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TABLE 3 | Clinical and gender-related factors in men according to pre-admission
medication adherence.
Low
adherence
(n = 43)
Medium-high
adherence
(n = 139)
p
Age, years median
[IQR]
65 [60–74] 69 [63–75] 0.157
BMI, kg/m2 median
[IQR]
27.5
[25.3–31.0]
27.1 [25.1–29.4] 0.576
SBP, mmHg median
[IQR]
120 [110–130] 120 [110–130] 0.200
DBP, mmHg median
[IQR]
80 [70–85] 80 [70–85] 0.973
HR, bpm median
[IQR]
70 [62–78] 69 [60–76] 0.279
Hypertension 37 (88.1) 123 (88.5) 0.944
Dyslipidemia 27 (62.8) 85 (61.2) 0.847
Type 2 diabetes 17 (39.5) 43 (30.9) 0.294
Active Smoke 13 (30.2) 36 (26.1) 0.593
Alcohol Abuse 10 (23.3) 32 (24.2) 0.895
Physical inactivity 33 (76.7) 104 (74.8) 0.798
History of CAD 23 (53.5) 61 (43.9) 0.270
Vascular disease 13 (31.0) 43 (30.9) 0.998
Stroke/TIA 4 (9.5) 14 (10.1) 0.917
CKD 9 (22.0) 32 (23.7) 0.816
Polypharmacy 25 (58.1) 72 (51.8) 0.466
DASI, median [IQR] 8.5 [3.0–14.0] 5.0 [2.0–11.5] 0.610
Employed status 25 (58.1) 46 (33.3) 0.004
Primary earner# 18 (54.5) 77 (73.3) 0.042
Male BSRI, median
[IQR]
5.2 [5.0–5.8] 4.9 [4.4–5.5] 0.059
Female BSRI,
median [IQR]
6.0 [5.1–6.4] 5.6 [5.−6.2] 0.581
High stress at
home#
5 (18.8) 19 (18.4) 0.969
Married/living with
partner
33 (76.7) 109 (78.4) 0.817
Low SES* 20 (46.5) 54 (38.8) 0.371
Data are presented as number of patients (%) unless otherwise specified.
IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HR, heart rate; CAD, coronary artery disease; TIA, Transient
ischemic attack; CKD, chronic kidney disease; DASI, Duke Activity Status Index; SES
socioeconomic status; BSRI, Bem Sex Role Inventory; *SES was defined based on low
education level and/or personal income. #data available for 135 men.
considering gender in the evaluation of clinical outcomes,
the first hurdle for researchers originates from the apparent
lack of standardized methods to measure the complexities
of all that gender encompasses. Recently, through a Pan-
Canadian collaboration of a multi-disciplinary team of scientists,
a comprehensive list of gender-related variables was established
and collected in the setting of premature cardiovascular disease
(23). Using the EVA cohort, we could now potentially describe
every dimension of gender through a granularity of data
which is rarely available. In the analysis adjusted for sex,
employment status was the only factor associated to medication
adherence: specifically, employed status has a negative influence
TABLE 4 | Clinical and gender-related factors in women according to
pre-admission medication adherence.
Low
adherence
(n = 24)
Medium-high
adherence
(n = 74)
p
Age, years median
[IQR]
72 [64–81] 74 [65–78] 0.568
BMI, kg/m2 median
[IQR]
26.3
[24.2–28.8]
24.9 [22.2–29.7] 0.435
SBP, mmHg median
[IQR]
130 [125–140] 130 [120–140] 0.315
DBP, mmHg median
[IQR]
75 [70–90] 70 [70–80] 0.259
HR, bpm median [IQR] 72 [60–80] 72 [65–77] 0.526
Hypertension 20 (83.3) 58 (78.4) 0.601
Dyslipidemia 14 (58.3) 37 (50.0) 0.478
Type 2 diabetes, 10 (41.7) 15 (20.3) 0.037
Active Smoke 2 (8.7) 13 (17.8) 0.294
Alcohol Abuse 1 (4.2) 4 (5.6) 0.781
Physical inactivity 24 (100.0) 63 (85.1) 0.045
History of CAD 5 (20.8) 18 (24.3) 0.726
Vascular disease 8 (33.3) 15 (20.3) 0.189
Stroke/TIA 3 (12.5) 10 (13.5) 0.899
CKD 8 (33.3) 21 (29.6) 0.730
Polypharmacy 13 (54.2) 34 (45.9) 0.484
DASI, median [IQR] 11 [7–25] 10 [6.8–15] 0.114
Employed status 2 (8.3) 11 (15.1) 0.401
Primary earner# 1 (5.9) 6 (9.5) 0.637
Male BSRI, median
[IQR]
4.3 [3.7–4.6] 4.6 [4.0–5.4] 0.106
Female BSRI, median
[IQR]
5.7 [5.0–6.8] 6.0 [5.6–6.6] 0.773
High stress at home# 8 (50.0) 25 (38.5) 0.400
Married/living with
partner
13 (54.2) 40 (54.1) 0.992
Low SES* 16 (66.7) 42 (56.8) 0.391
Data are presented as number of patients (%) unless otherwise specified.
IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HR, heart rate; CAD, coronary artery disease; TIA, Transient
ischemic attack; CKD, chronic kidney disease; DASI, Duke Activity Status Index; SES
socioeconomic status; BSRI, Bem Sex Role Inventory; *SES was defined based on low
education level and/or personal income. #data available for 80 women.
TABLE 5 | Multivariate logistic regression of pre-admission medication adherence
in patients admitted for ischemic heart disease.
OR 95% CI p
OVERALL
Employed status 0.55 0.31–0.97 0.041
MALE PATIENTS
Male BSRI 0.59 0.35–0.99 0.048
FEMALE PATIENTS
Type 2 diabetes 0.36 0.13–0.96 0.041
OR, Odds Ratio; CI, confidence interval; BSRI, Bem Sex Role Inventory.
on adherence to therapy. This difference in adherence between
unemployed and employed could be attributed to the busy
work schedules of working patients, which could interfere
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with adequate behaviors of self-care. However, in literature,
the link between employed status and medication adherence
has been barely explored. Our findings have therefore raised
important unexplored questions on the mechanisms explaining
the association between gender roles and medication adherence
in patients at high cardiovascular risk. Apart from work status,
personality traits (considered as expressions of gender identity)
seem to play a pivotal role in medication adherence (41, 42).
It was reported that some personality traits such as emotional
stability, interpersonal orientation, and motivation in goal-
directed behavior are associated to medication adherence in
individuals with chronic disease (41). In this light, we observed
that beyond clinical characteristics, a higher BSRI masculine
score, calculated on personality traits (including risk-taking
behavior, independence, competitiveness, strong personality,
etc.) can be negatively associated to pre-admission medication
adherence in men hospitalized for IHD. This finding may be
explained by the tendency of male patients with these personality
traits to put high trust in their own ability to manage their health,
therefore underestimating the importance of adherence to health
providers’ prescriptions (41, 43).
The present analysis has several strengths worth mentioning.
We were uniquely positioned to evaluate all 4 dimensions that
gender constructs encompass in a “real-world,” contemporary
cohort of patients with IHD.We also had a granularity in the data
exploring gender constructs which is largely uncommon. Finally,
as recommended by international societies and funding agencies
(39, 40), we could report the data disaggregated by sex.
Limitations
Some important limitations of the present analysis must be
stated. As any observational cohort study, some confounders
might not have been assessed and could influence our final
multivariate model, as could any missing data points.
Furthermore, the sample size is small, and the EVA study
was not specifically designed to test the effect of diabetes on
pre-admission medication adherence outcomes. The lack of
statistical significance in the effect of sex or gender-related
factors may be due to the lack of power to address specific
differences. We cannot exclude that, as the sample increases,
some relevant differences might emerge. Moreover, the findings
refer to a selected cohort of patients at very high cardiovascular
risk, hospitalized for an ischemic event, at a single center in
Italy, limiting the generalizability of our results. We cannot
account for countries with specific differences in psychosocial
and cultural factors.
Finally, medication adherence is related to the global patient
assumption of drugs pre-admission, yet we cannot describe the
nuances of adherence separately for each class of drugs, such as
glucose lowering drugs or cardiovascular preventive drugs (i.e.,
anti-platelets or statins).
Future Directions
Overall, the present analysis highlights the importance of
considering the different effects of clinical characteristics
(e.g., diabetes) and gender-related factors (e.g., personality
traits or employment status) among women and men, in
order to better identify and target high-risk subgroups of
patients. The impact of pre-admission medication adherence
on clinical outcomes in IHD patients, including diabetics,
is a surprisingly underestimated issue (13) which requires
further investigation (44, 45). Clinicians should consider the
use of prior medication adherence as an indicator of future
medication-taking behavior.
Future studies—powered and able to apply a gender
transformative framework (46) in the consideration of the
specific research questions—are warranted, with the overarching
aim to ultimately design effective interventions to promote health
and well-being.
New approaches such as big data analysis (47) across
patient data registries across countries could be interesting
avenues to explore the impact of gender-related factors as
determinants of clinically relevant outcomes on a larger,
population-based scale.
CONCLUSION
Poor medication adherence is still a highly prevalent condition
in patients at high cardiovascular risk. Medication adherence
recognizes disease-centered and patient-centered determinants.
Among them, gender-related factors (i.e., personality traits
and gender role) and diabetes are associated in a sex-specific
manner with pre-admission medication adherence of patients
hospitalized for IHD. Future clinical trials should test if
sex-specific and gender-sensitive interventions might improve
medication adherence in high cardiovascular risk conditions,
such as women with diabetes.
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